Sarepta shares slide as DMD treatment woes pile up

The ESSENCE trial of Sarepta's Vyondys 53 and Amondys 45 failed to hit its objective, placing their FDA accelerated approvals at risk.

Surfing on new Duchenne data, Wave charges $175m offering

Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to its highest level in a year and could lead to discussions with re

FDA says no to Sarepta's golodirsen, blocking bid to expand ...